세계의 캐리어 스크리닝 시장(-2028년) : 제품 및 서비스별, 유형별(확대(맞춤형, 사전설계), 대상 질환), 질환별(혈액, 폐), 기술별(DNA 시퀀싱, PCR), 최종사용자별, 지역별
Carrier Screening Market by Product and Service, Type (Expanded (Customized, Predesigned) Targeted Diseases), Medical condition (Hematologic, Pulmonary), Technology (DNA Sequencing, PCR), End user, Region - Global Forecast to 2028
상품코드:1421503
리서치사:MarketsandMarkets
발행일:2024년 01월
페이지 정보:영문 224 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
보고서 개요
세계 캐리어 스크리닝 시장 규모는 2023년 22억 달러에서 예측 기간 동안 19.7%의 CAGR을 기록하며 2028년에는 54억 달러 규모로 성장할 것으로 예상됩니다.
시장을 이끄는 요인으로는 차세대 염기서열 분석(NGS)과 같은 유전자 검사 기술의 지속적인 발전으로 인해 캐리어 스크리닝의 효율성, 정확성 및 비용 효율성이 향상되고, 유전성 질환의 유병률이 증가함에 따라 다양한 질환의 유전적 기반에 대한 이해도가 높아진 점 등이 있습니다.
조사 범위
조사 대상 연도
2021-2028년
기준 연도
2022년
예측 기간
2023-2028년
단위
금액(달러)
부문
제품 및 서비스별, 유형별, 질환별, 기술별, 최종사용자별, 지역별
대상 지역
북미(미국, 캐나다), 유럽(독일, 프랑스, 영국, 스페인, 이탈리아, 기타), 아시아태평양(중국, 인도, 일본, 기타), 기타 지역(라틴아메리카, 중동 및 아프리카, GCC 국가)
질환별로는 신경질환 부문이 예측 기간 동안 두 번째로 큰 비중을 차지할 것으로 예상됩니다. 헌팅턴병, 근위축성 측삭경화증(ALS), 간질과 같은 질환의 유전적 기초를 이해하는 것은 이러한 질환이 미래 세대에 전달될 위험을 평가하는 데 매우 중요합니다. 마찬가지로, 신경질환의 보균자 선별검사는 유전적 위험 요인을 조기에 발견할 수 있게 해줍니다. 조기 보인자 확인은 개인이나 부부가 충분한 정보를 바탕으로 생식 결정을 내릴 수 있는 기회를 제공하고, 계획 단계 초기에 개입과 치료를 고려할 수 있는 기회를 제공합니다.
기술별로는 PCR 기술 부문이 두 번째로 높은 점유율을 보이고 있으며, PCR 기술은 특정 DNA 염기서열을 증폭하고 검출하는 데 있어 높은 민감도와 특이성을 가지고 있는 것으로 알려져 있습니다. 이러한 정확성은 다양한 질병과 관련된 유전자 돌연변이의 보균자를 확실하게 식별하기 위한 캐리어 스크리닝에 있어 매우 중요합니다. 마찬가지로, PCR은 한 번의 반응으로 여러 개의 표적 DNA 서열을 증폭할 수 있는 다중화(multiplexing) 기능을 제공합니다. 이 기능은 캐리어 스크리닝에 매우 유용합니다.
세계의 캐리어 스크리닝 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술 및 특허 동향, 규제 환경, 시장 규모 추이 및 예측, 각종 부문별·지역별 상세 분석, 경쟁 상황, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 주요 인사이트
제5장 시장 개요
시장 역학
성장 촉진요인
성장 억제요인
기회
과제
동향
가격 분석
밸류체인 분석
공급망 분석
Porter's Five Forces 분석
생태계/시장 맵
관세와 규제 상황
특허 분석
고객의 비지니스에 영향을 미치는 동향/디스럽션
주요 회의와 이벤트
기술 분석
주요 이해관계자와 구입 기준
무역 분석
제6장 캐리어 스크리닝 시장 : 제품 및 서비스별
서비스
제품
제7장 캐리어 스크리닝 시장 : 유형별
확대형 캐리어 스크리닝
사전설계 패널 테스트
맞춤형 패널 테스트
표적 질환 캐리어 스크리닝
제8장 캐리어 스크리닝 시장 : 질환별
폐질환
혈액질환
신경질환
기타
제9장 캐리어 스크리닝 시장 : 기술별
DNA 시퀀싱
PCR
DNA 마이크로어레이
기타
제10장 캐리어 스크리닝 시장 : 최종사용자별
병원·의료 센터
임상 실험실
불임 클리닉
기타
제11장 캐리어 스크리닝 시장 : 지역별
북미
유럽
아시아태평양
기타 지역
제12장 경쟁 상황
개요
주요 전략/유력 기업
시장 점유율 분석
매출 점유율 분석
기업 평가 매트릭스
스타트업/중소기업 평가 매트릭스
경쟁 시나리오와 동향
제13장 기업 개요
주요 기업
NATERA, INC.
QUEST DIAGNOSTICS INCORPORATED
FULGENT GENETICS
INVITAE CORPORATION
EUROFINS SCIENTIFIC
OPKO HEALTH, INC.
THERMO FISHER SCIENTIFIC INC.
MYRIAD GENETICS, INC.
ILLUMINA, INC.
LABORATORY CORPORATION OF AMERICA HOLDINGS
CENTOGENE N.V.
DIASORIN S.P.A.
BGI
OTOGENETICS
GENETECH
기타 기업
OXY-GEN LABORATORY LLC
MEDGENOME
AMBRY GENETICS.
ASPER BIOGENE
LIFELABS GENETICS
EASYDNA
LIFECELL
CNC PATH LAB
SIGNATURE DIAGNOSTICS INC.
MITERA
제14장 부록
ksm
영문 목차
영문목차
Report Description
The global Carrier Screening Market is expected to reach USD 5.4 Billion by 2028 from USD 2.2 Billion in 2023, at a CAGR of 19.7% during the forecast period. Market is driven by factors such as Ongoing advancements in genetic testing technologies, such as next-generation sequencing (NGS), improve the efficiency, accuracy, and cost-effectiveness of carrier screening, The increasing prevalence of genetic disorders, coupled with a greater understanding of the genetic basis of various conditions On the other hand, The demand for genetic counseling services often exceeds the available resources. A shortage of genetic counselors can hinder the delivery of comprehensive counseling to individuals undergoing carrier screening, potentially limiting the understanding and interpretation of results.
Scope of the Report
Years Considered for the Study
2021-2028
Base Year
2022
Forecast Period
2023-2028
Units Considered
Value (USD) Billion
Segments
Product & Service, Type, Medical Condition, Technology, End User, and Region
Regions covered
North America (US, Canada), Europe (Germany, France, UK, Spain, Italy, and RoE), APAC (China, India, Japan, and the RoAPAC), and Rest of the World (Latin America, Middle East & Africa, GCC countries)
"The Neurological Conditions accounted for the second largest market share in the carrier screening market product' s market, during the forecast period"
Based on the Medical Conditions, Carrier Screening Market is classified into Hematologic Conditions, Pulmonary Conditions, Neurological Conditions, and Others. In 2022, Neurological Conditions accounted for a sizable market share because Many neurological disorders have a genetic component. Understanding the genetic basis of conditions such as Huntington's disease, amyotrophic lateral sclerosis (ALS), and certain forms of epilepsy can be crucial for assessing the risk of passing on these conditions to future generations. Likewise, Carrier screening for neurological conditions allows for early detection of genetic risk factors. Early identification of carriers provides an opportunity for individuals and couples to make informed reproductive decisions and consider interventions or therapies early in the planning stages.
"PCR technology segment accounted for the second largest market share"
Based on type on technology, the carrier screening market is segmented into DNA Sequencing, PCR, DNA Microarray, and Other. The PCR technology segment accounted for the second largest market share in 2022., due to its variety of applications such as PCR technology is known for its high sensitivity and specificity in amplifying and detecting specific DNA sequences. This accuracy is crucial in carrier screening to reliably identify carriers of genetic mutations associated with various disorders, likewise, PCR allows for the amplification of multiple target DNA sequences in a single reaction, a feature known as multiplexing. This capability is valuable in carrier screening,
"APAC region accounted for the third highest CAGR"
The global Carrier Screening market is divided into four regions: North America, Asia-Pacific, Europe, and Rest of the World. According to the regional analysis, the Asia-Pacific region is likely to retain a considerable market share in 2022 and the future. The Asia-Pacific market is being propelled by an rising cases of rare disease, rising in healthcare expenditure, rising in awareness about early disease diagnosis.
"Europe is estimated to register the second highest CAGR during the forecast period."
In this report, the Carrier Screening market is segmented into four major regional segments: North America, Europe, Asia Pacific, Rest of the world. The market in Europe is projected to register the second highest growth rate during the forecast period. The growth in this market is due to Europe has a strong tradition of research and academic excellence, the rising incidence of genetic and rare diseases, government funding for research and healthcare in many European countries supports the development and adoption of advanced diagnostic technologies such as carrier screening.
The primary interviews conducted for this report can be categorized as follows:
By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
By Designation: C-level - 30%, D-level - 34%, and Others - 36%
By Region: North America - 40%, Europe - 28%, Asia Pacific - 20%, and the Rest of the World - 12%
Lits of Companies Profiled in the Report:
Invitae Corporation. (US)
Fulgent Genetics.(US)
Eurofins Scientific (Germany)
OPKO Health, Inc.(US)
Thermo Fisher Scientific Inc.(US)
Quest Diagnostics Incorporated (US)
Myriad Genetics, Inc (US)
Illumina, Inc.(US)
Natera, Inc.(Italy)
Laboratory Corporation of America Holdings.(US)
CENTOGENE N.V.(Germany)
DiaSorin S.p.A.(Italy)
BGI (China)
Otogenetics (US)
GeneTech (India)
Signature Diagnostics Inc.(US)
MedGenome (US)
Ambry Genetics.(US)
Asper Biogene (Estonia)
LifeLabs Genetics (Canada)
EasyDNA (US)
LifeCell (India)
CNC Path Lab (India)
Oxy-Gen Laboratory LLC (US)
Mitera (US)
Research Coverage:
This report studies the Carrier Screening market based on Product & Service, Type, Medical Condition, Technology, End User, and Region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Carrier Screening market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
Market Drivers: Comprehensive information about driving factors of the markets. The report analyses the markets drivers across key geographic regions.
Market Penetration: Comprehensive information on Carrier Screening Market products offered by the top 25 players in the market. The report analyses the Carrier Screening market by Product & Service, Type, Medical Condition, Technology, End User, and Region.
Market Development: Comprehensive information about lucrative emerging markets. The report analyses the markets for various securement devices across key geographic regions.
Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the Carrier Screening market
Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the Carrier Screening market
Market Position: It will upkeep stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS COVERED
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT: CARRIER SCREENING MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
FIGURE 2 KEY SECONDARY SOURCES
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primary interviews
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
TABLE 173 GCC COUNTRIES: CARRIER SCREENING MARKET, BY MEDICAL CONDITION, 2021-2028 (USD MILLION)
TABLE 174 GCC COUNTRIES: CARRIER SCREENING MARKET, BY END USER, 2021-2028 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
TABLE 175 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CARRIER SCREENING MARKET
12.3 MARKET SHARE ANALYSIS
TABLE 176 DEGREE OF COMPETITION: CARRIER SCREENING MARKET
12.4 REVENUE SHARE ANALYSIS
FIGURE 34 REVENUE SHARE ANALYSIS OF KEY PLAYERS
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 35 COMPANY EVALUATION MATRIX, 2022
12.5.5 COMPANY FOOTPRINT
TABLE 177 OVERALL COMPANY FOOTPRINT
TABLE 178 PRODUCT FOOTPRINT
TABLE 179 REGIONAL FOOTPRINT
12.6 START-UP/SME EVALUATION MATRIX
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 36 START-UP/SME EVALUATION MATRIX, 2022
12.6.5 COMPETITIVE BENCHMARKING
TABLE 180 DETAILED LIST OF KEY START-UPS/SMES IN CARRIER SCREENING MARKET
12.7 COMPETITIVE SCENARIOS AND TRENDS
12.7.1 KEY DEALS
TABLE 181 KEY DEALS, JANUARY 2020-DECEMBER 2023
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats)**
13.1.1 NATERA, INC.
TABLE 182 NATERA, INC.: COMPANY OVERVIEW
FIGURE 37 NATERA, INC.: COMPANY SNAPSHOT (2022)
13.1.2 QUEST DIAGNOSTICS INCORPORATED
TABLE 183 QUEST DIAGNOSTICS INCORPORATED: COMPANY OVERVIEW
FIGURE 38 QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT (2022)
13.1.3 FULGENT GENETICS
TABLE 184 FULGENT GENETICS: COMPANY OVERVIEW
FIGURE 39 FULGENT GENETICS.: COMPANY SNAPSHOT (2022)
13.1.4 INVITAE CORPORATION
TABLE 185 INVITAE CORPORATION: COMPANY OVERVIEW
FIGURE 40 INVITAE CORPORATION.: COMPANY SNAPSHOT (2022)
13.1.5 EUROFINS SCIENTIFIC
TABLE 186 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
FIGURE 41 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
13.1.6 OPKO HEALTH, INC.
TABLE 187 OPKO HEALTH, INC.: COMPANY OVERVIEW
FIGURE 42 OPKO HEALTH, INC.: COMPANY SNAPSHOT (2022)
13.1.7 THERMO FISHER SCIENTIFIC INC.
TABLE 188 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
13.1.8 MYRIAD GENETICS, INC.
TABLE 189 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
FIGURE 44 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2022)
13.1.9 ILLUMINA, INC.
TABLE 190 ILLUMINA, INC.: COMPANY OVERVIEW
FIGURE 45 ILLUMINA, INC.: COMPANY SNAPSHOT (2022)
13.1.10 LABORATORY CORPORATION OF AMERICA HOLDINGS
TABLE 191 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
FIGURE 46 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
13.1.11 CENTOGENE N.V.
TABLE 192 CENTOGENE N.V.: COMPANY OVERVIEW
FIGURE 47 CENTOGENE N.V.: COMPANY SNAPSHOT (2022)
13.1.12 DIASORIN S.P.A.
TABLE 193 DIASORIN S.P.A.: COMPANY OVERVIEW
FIGURE 48 DIASORIN S.P.A.: COMPANY SNAPSHOT (2023)
13.1.13 BGI
TABLE 194 BGI: COMPANY OVERVIEW
13.1.14 OTOGENETICS
TABLE 195 OTOGENETICS: COMPANY OVERVIEW
13.1.15 GENETECH
TABLE 196 GENETECH: COMPANY OVERVIEW
13.2 OTHER PLAYERS
13.2.1 OXY-GEN LABORATORY LLC
TABLE 197 OXY-GEN LABORATORY LLC: COMPANY OVERVIEW
13.2.2 MEDGENOME
TABLE 198 MEDGENOME: COMPANY OVERVIEW
13.2.3 AMBRY GENETICS.
TABLE 199 AMBRY GENETICS: COMPANY OVERVIEW
13.2.4 ASPER BIOGENE
TABLE 200 ASPER BIOGENE: COMPANY OVERVIEW
13.2.5 LIFELABS GENETICS
TABLE 201 LIFELABS GENETICS: COMPANY OVERVIEW
13.2.6 EASYDNA
TABLE 202 EASYDNA: COMPANY OVERVIEW
13.2.7 LIFECELL
TABLE 203 LIFECELL: COMPANY OVERVIEW
13.2.8 CNC PATH LAB
TABLE 204 CNC PATH LAB: COMPANY OVERVIEW
13.2.9 SIGNATURE DIAGNOSTICS INC.
TABLE 205 SIGNATURE DIAGNOSTICS INC.: COMPANY OVERVIEW
13.2.10 MITERA
TABLE 206 MITERA: COMPANY OVERVIEW
*Details on Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
